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Abstract
Background: The safety of restarting angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor
blockers (ARB) after acute kidney injury (AKI) is unclear. There is concern that previous users do not restart ACEI/ARB
despite ongoing indications. We sought to determine the risk of adverse events after an episode of AKI, comparing
prior ACEI/ARB users who stop treatment to those who continue.
Methods: We conducted two parallel cohort studies in English and Swedish primary and secondary care, 2006–
2016. We used multivariable Cox regression to estimate hazard ratios (HR) for hospital admission with heart failure
(primary analysis), AKI, stroke, or death within 2 years after hospital discharge following a first AKI episode. We
compared risks of admission between people who stopped ACEI/ARB treatment to those who were prescribed
ACEI/ARB within 30 days of AKI discharge. We undertook sensitivity analyses, including propensity score-matched
samples, to explore the robustness of our results.
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Results: In England, we included 7303 people with AKI hospitalisation following recent ACEI/ARB therapy for the
primary analysis. Four thousand three (55%) were classified as stopping ACEI/ARB based on no prescription within
30 days of discharge. In Sweden, we included 1790 people, of whom 1235 (69%) stopped treatment. In England, no
differences were seen in subsequent risk of heart failure (HR 1.10; 95% confidence intervals (CI) 0.93–1.30), AKI (HR
0.90; 95% CI 0.77–1.05), or stroke (HR 0.99; 95% CI 0.71–1.38), but there was an increased risk of death (HR 1.27; 95%
CI 1.15–1.41) in those who stopped ACEI/ARB compared to those who continued. Results were similar in Sweden:
no differences were seen in risk of heart failure (HR 0.91; 95% CI 0.73–1.13) or AKI (HR 0.81; 95% CI 0.54–1.21).
However, no increased risk of death was seen (HR 0.94; 95% CI 0.78–1.13) and stroke was less common in people
who stopped ACEI/ARB (HR 0.56; 95% CI 0.34–0.93). Results were similar across all sensitivity analyses.
Conclusions: Previous ACEI/ARB users who continued treatment after an episode of AKI did not have an increased
risk of heart failure or subsequent AKI compared to those who stopped the drugs.
Keywords: Acute kidney injury, Heart failure, Angiotensin-converting enzyme inhibitor (ACEI), Angiotensin II
receptor blocker (ARB)
Background
Acute kidney injury (AKI) is a sudden (over hours or
days) deterioration in kidney function, strongly associ-
ated with a range of adverse outcomes, particularly an
increase in subsequent admission with heart failure [1,
2]. Risk factors for AKI include diabetes, chronic kidney
disease, hypertension, and heart failure with reduced
ejection fraction (HFrEF) [3]. ACE inhibitors (ACEI) and
angiotensin II receptor blockers (ARB) are commonly
used, evidence-based treatments for these conditions,
and thus, many people admitted to hospital with AKI
are treated with these medications. It is widely believed
that in the setting of acute intercurrent illness, ACEI/
ARB can cause or exacerbate AKI. Internationally, strat-
egies have been developed to improve outcomes from
AKI, and among these are guidance to temporarily re-
duce or stop ACEI/ARB in acutely unwell people with
the aim of preventing or reducing the severity of AKI
[4–6]. However, there is concern that people who have
medication stopped during acute illness may not have it
restarted, which may result in adverse outcomes, par-
ticularly decompensation for those with HFrEF [3].
Evidence about the comparative risks of cardiovascular
and kidney outcomes for people who have ACEI/ARB
medications stopped after an episode of AKI is limited.
The lack of clear guidance about whether, and when, to
restart treatment suggests a degree of variation in care
regarding post-AKI exposure to ACEI/ARB; in this situ-
ation, observational research may provide valuable
insights.
Therefore, we sought to examine prescribing of ACEI/
ARB after a first episode of AKI and determine the risks
of subsequent hospital admission with heart failure, fur-
ther AKI, or stroke, and the risk of death, comparing
people who stopped treatment with those where ACEI/
ARB was continued in primary care after hospital
discharge. To ensure the robustness of our results, we
undertook this analysis in England and Sweden to com-
pare effects in different data sources, with different pri-
mary health care systems and differing recognition and
coding of AKI.
Methods
Study design and setting
English cohort
This was a population-based cohort using linked data
from the UK Clinical Practice Research Datalink (CPRD-
GOLD) and Hospital Episode Statistics (HES) databases.
CPRD-GOLD contains primary care data for approxi-
mately 7% of the current UK population and is largely
representative of that population in terms of age, sex,
and ethnicity [7]. It contains data on clinical symptoms
and diagnoses recorded using Read codes and prescrip-
tion data. HES records include all hospital admission
data for National Health Service (NHS)-funded patients
in England. We used only CPRD-HES linked data, which
is available for approximately 60% of general practices
contributing to CPRD and limits the analysis to people
contributing to CPRD from England [8]. The study
period was 1 January 2010 to 31 December 2016. We re-
stricted the study period in the UK to more recent years
because awareness and coding of AKI has markedly in-
creased since 2010 [9].
Swedish cohort
The Swedish cohort used data from the Stockholm CRE-
Atinine Measurements (SCREAM) healthcare utilisation
cohort, which includes all Stockholm residents (Sweden)
accessing healthcare with at least one plasma creatinine
measured during 2006–2011 [10, 11]. SCREAM includes
data from ~ 1.3 million adults, corresponding to 68% of
the region for the study period. Laboratory results were
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linked with regional and national administrative data-
bases for complete information on demographic data,
healthcare use (both inpatient and outpatient care), diag-
noses, dispensed drugs at Swedish pharmacies, and
death.
Participants
English cohort
Study participants were aged 18 years or over and met
criteria for research-standard data during the study
period, with at least 1 year of continuous registration be-
fore the study entry to ensure reliable measures of drug
use and baseline covariates. Participants were included
at the first recorded hospital admission with AKI defined
using International Classification of Diseases (ICD)-10
code N17 in the first or second diagnostic position in
HES data in any episode within 1 week of admission.
The N17 code has a positive predictive value for AKI of
95% in an English single-centre study [12]. We then re-
stricted to participants prescribed ACEI/ARB within 60
days before the AKI admission. We excluded people
with a history of AKI admission before 2010, end-stage
renal disease (ESRD) in primary care records, or dialysis
procedure codes in secondary care records before the
AKI admission.
Swedish cohort
We defined participants included in the Swedish cohort
in the same way as in England, except that we identified
those included based on a dispensed prescription for
ACEI/ARB within 180 days before the AKI admission
(rather than 60 days in England) because of the longer
duration of prescriptions in Sweden. We excluded
people admitted for AKI before 2006 or with a history of
previous dialysis or transplant.
Exposure
We compared people who stopped ACEI/ARB therapy
to those who continued the drugs. In the primary ana-
lysis, individuals stopping therapy were defined as those
with no record of being prescribed an ACEI/ARB in pri-
mary care (English cohort) or dispensed an ACEI/ARB
from a pharmacy (Swedish cohort) within 30 days fol-
lowing the baseline AKI discharge. Individuals continu-
ing therapy were defined as those who were prescribed
or dispensed an ACEI/ARB within the same period. The
30-day period was chosen to allow for medication pre-
scribed on discharge, stockpiled medication, and delays
in attending their primary care doctor to arrange a re-
peat prescription. Inspection of the data confirmed that
most ACEI/ARB prescriptions occurred within 30 days
of discharge.
Outcomes
The primary outcome was a hospital admission with
heart failure, defined by ICD-10 coding in the first or
second diagnostic position of the first episode in HES in-
patient data (English cohort) or hospital discharge re-
cords (Swedish cohort) during the follow-up period.
Secondary outcomes were hospital admission for AKI
and stroke (similarly defined) and death from all causes.
For the Swedish cohort, ICD-10 codes used to define
outcomes were based on validated algorithms in the
Swedish health care setting [13]. To avoid immortal time
bias, follow-up for all participants began 30 days post-
AKI discharge; after this time, the exposure group could
be definitively assigned to all participants. We excluded
people who ended follow-up in the database (e.g. moved
to a non-participating GP (English cohort), migrated out
of the region of Stockholm (Swedish cohort)), died, or
had the outcome of interest during the first 30 days after
AKI discharge. The latter exclusion was outcome-
specific, so a participant readmitted with heart failure
within the first 30 days would be excluded from the
heart-failure-outcome analysis post-30 days, but
remained eligible for inclusion in analyses of other out-
comes (AKI, stroke, death). During included follow-up
(≥ 30 days from discharge), participants having one type
of outcome were similarly considered to remain at risk
for other outcomes after that date. We followed partici-
pants for a maximum of 2 years to minimise the influ-
ence on outcomes of later events and changes in
prescribing. The study design is shown graphically in
Additional file 1: Figure S1.
Covariates
English cohort
We chose covariates for multivariable model adjustment
and propensity score matching a priori, based on previ-
ous knowledge. We included age, sex, smoking, alcohol
intake, body mass index (BMI) [14], and calendar year
(to account for the changes in practice that have influ-
enced drug prescribing and coding of hospital out-
comes). We also considered other confounders including
baseline comorbidities (arrhythmia, diabetes, heart fail-
ure, hypertension, ischaemic heart disease) defined using
morbidity coding in primary care (Read codes) or as part
of a hospital admission (ICD-10 codes) any time prior to
the baseline AKI admission. Heart failure was a critical
baseline comorbidity that may be incompletely captured
by Read codes in CPRD [15], so this was additionally de-
fined by a prescription for spironolactone within 60 days
before baseline AKI admission [15]. We adjusted for
baseline kidney function by calculating the estimated
glomerular filtration rate (eGFR) using the most recent
serum creatinine recorded in participants’ primary care
records (excluding any measures within 7 days before
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baseline AKI admission) and using the CKD-EPI equa-
tion, assuming non-black ethnic origin for all [16]. eGFR
was categorised using the cut-points of the Kidney Dis-
ease Improving Global Outcomes guidelines for chronic
kidney disease (CKD), but without the requirement for
two measures 3 months apart [17]. Where eGFR was
missing, we assigned a ‘no known CKD’ category as in
this population missing serum creatinine data is associ-
ated with outcomes closely equivalent to normal kidney
function [18]. We also adjusted for concomitant pre-
scriptions for loop diuretics, beta-blockers, and calcium
channel blockers, defined by a prescription within the
60 days before the baseline AKI admission.
Swedish cohort
We adjusted for similar covariates to those used in
England, except that we defined all variables at 30 days
post AKI discharge (the inception point for the cohort).
We could not capture BMI, ethnicity, smoking, or alco-
hol intake in Swedish data. Spironolactone use was ad-
justed for as a concomitant medication.
Analysis
In both the English and Swedish cohorts, after confirm-
ing the proportional hazard assumption was met, we
used Cox regression to estimate adjusted hazard ratios
(HR) for admission with heart failure (primary analysis),
AKI, stroke, and death, comparing participants who
stopped treatment with those who were prescribed
(England) or dispensed (Sweden) an ACEI/ARB within
30 days after discharge. Given the low level of missing
data (8% of English participants for one or more covari-
ates, none in the Swedish cohort) and that data were
unlikely to be missing at random, we used a complete-
case approach. In England, analysis was conducted using
Stata version 15.1 (StataCorp, Texas) and R version
3.5.0, and in Sweden, R version 3.4.2.
Sensitivity analyses
To maximise comparability between our exposure
groups, we conducted propensity-score-matched ana-
lyses to estimate the HRs for each study outcome. We
used logistic regression to calculate the odds of stopping
or being prescribed ACEI/ARB by the start of follow-up
for each year, adjusting for relevant covariates. Factors
included in the propensity score model were all covari-
ates described previously; plus in the English cohort, we
also adjusted for frailty using the electronic frailty index
(eFI) as a covariate, including both the frailty category
(fit, mildly, moderately or severely frail) and the individ-
ual components comprising the score [19]. We did not
adjust for eFI in the primary analysis to maintain com-
parability with the Swedish cohort where these data were
not available. Participants who stopped ACEI/ARB were
matched 1:1 on propensity score to participants who
continued therapy, using nearest neighbour matching
with a calliper of 0.2. We measured standardised mean
differences (SMD) for each covariate to check for bal-
ance between groups, with an SMD < 10% indicating
acceptable balance. We estimated HR using Cox regres-
sion for admission with heart failure, AKI, and stroke
and for death comparing those who stopped ACEI/ARB
with those who continued the drugs.
In addition, in both cohorts unless specified, we con-
ducted further sensitivity analyses. Firstly, we defined
people as having stopped ACEI/ARB if they had not re-
ceived an ACEI/ARB prescription in primary care by 60
days after discharge following their AKI admission (ra-
ther than 30 days in the main analysis). Secondly, to in-
crease certainty that participants were regular users of
ACEI/ARB, we restricted the cohort to people who had
at least two prescriptions for ACEI/ARB within 60 days
before the baseline AKI admission, one of which was
within 30 days before admission (England only). Thirdly,
we restricted outcome events to those recorded in the
first diagnostic position in English or Swedish hospital
records only (in the main analysis, we used the first and
second diagnostic positions). Fourth, we determined
HRs for all outcomes after excluding people who re-
quired dialysis during their initial AKI admission (Eng-
land only). Fifth, we conducted stratified analysis in
three time intervals (0–29, 30–89, and 90+ days after
start of follow-up) to consider changes over time in the
risk of re-admission and death in participants who
stopped ACEI/ARB compared with those who contin-
ued. Finally, we repeated all analyses excluding people
who were readmitted to hospital in the first 30 days after
the index AKI discharge.
Patient involvement
No patients were involved in setting the research ques-
tion or the outcome measures, nor were they involved in
developing plans for design or implementation of the
study. No patients were asked to advise on interpretation
or writing up of results. We are not able to disseminate
the results of the research directly to study participants
because the data used in both cohorts were de-
identified.
Results
Study populations and baseline characteristics
We included 8566 people in the English cohort and
2024 in the Swedish cohort (Fig. 1). Total follow-up time
for the primary outcome (heart failure) was 8215
person-years in the English cohort and 2445 person-
years in the Swedish cohort. In the English cohort, AKI
was listed in the 1st diagnostic position in hospital data
for 38% of participants (Additional file 1: Table S1). For
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62%, AKI was listed in the 2nd diagnostic position, and
for these people, infections were the most common
group of primary diagnoses.
Baseline characteristics for the English and Swedish
cohorts in the heart-failure-outcome analysis, stratified
by stopping or continuing ACEI/ARB, are shown in
Table 1. Comparisons between the English and Swedish
cohorts for all participants discharged after AKI and
those included in the heart-failure-outcome analyses are
shown in Additional file 1: Table S2. The cohorts for the
primary analysis were similar between countries with a
mean age of 77 years and 75 years in England and
Sweden respectively, 53% and 55% men, and similar
mean baseline eGFR 54 mL/min/1.73 m2 (standard devi-
ation [SD] ~ 23). Slightly more participants in the
English cohort were diabetic (47%) compared with the
Swedish cohort (43%). A lower proportion of the English
cohort was classified as having heart failure (30%) com-
pared with the Swedish cohort (47%).
ACEI/ARB prescriptions
In England, of all people discharged from hospital fol-
lowing an admission with AKI, 45% (3833/8566) had not
been prescribed ACEI/ARB by 90 days after hospital dis-
charge (Additional file 1: Figure S2A). Of the people
who did continue ACEI/ARB, 75% (3565/4733) had been
prescribed the drugs by 30 days after discharge and 93%
(4402/4733) at 60 days. In the heart-failure-outcome
analysis, 55% (4003/7303) were classified as stopping
ACEI/ARB based on no issued prescription within 30
days of discharge. The proportion of people prescribed
ACEI/ARB after discharge in England increased progres-
sively from 2010 (Additional file 1: Figure S3).
In the Swedish cohort, a higher proportion of
people (53% (1083/2024)) had not been dispensed a
prescription for ACEI/ARB from their pharmacy at
90 days post-discharge after admission with AKI
(Additional file 1: Figure S2B). Of the people who did
continue ACEI/ARB treatment, 67% (628/941) were
dispensed a prescription within 30 days after discharge
and 82% (771/941) at 60 days. In the heart-failure-
outcome analysis, 69% (1235/1790) were classified as
stopping ACEI/ARB based on no dispensed prescrip-
tion within 30 days of discharge.
Characteristics of people who stopped or continued
treatment were generally similar, although in the English
cohort category G4 and G5 eGFR tended to be more
common in those who stopped ACEI/ARB compared
with those who continued (14% compared with 10%, re-
spectively), as was dialysis during admission (5% vs 2%).
In both cohorts, participants were slightly more likely to
continue ACEI/ARB after discharge with AKI if they had
baseline heart failure (32% vs 29% in England and 51%
vs 46% in Sweden), diabetes (48% vs 46% in England and
47% vs 41% in Sweden), or ischaemic heart disease (54%
vs 50% in England and 38% vs 36% in Sweden).
Fig. 1 Flow diagram for study participant identification
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Table 1 Baseline characteristics of the English and Swedish cohorts included in the heart failure (primary outcome) analysis
English cohort Swedish cohort
Continued ACEI/ARB Stopped ACEI/ARB Continued ACEI/ARB Stopped ACEI/ARB
N = 3300 N = 4003 N = 555 N = 1235
Age (years), mean (SD) 77 (11) 77 (11) 75 (12) 75 (12)
Age (years)
18–69 756 (23) 914 (23) 179 (32) 393 (32)
70–74 386 (12) 482 (12) 73 (13) 162 (13)
75–79 609 (19) 731 (18) 80 (14) 161 (13)
80–84 672 (20) 827 (21) 94 (17) 214 (17)
85–89 552 (17) 655 (16) 85 (15) 201 (16)
≥ 90 325 (10) 394 (10) 44 (8) 104 (8)
Women 1569 (48) 1862 (47) 255 (46) 550 (45)
Baseline eGFR (ml/min/1.73 m2), mean (SD) 55 (21) 53 (22) 53 (23) 55 (24)
eGFR category
No known CKD 388 (12) 487 (12) 25 (5) 102 (8)
G1-No CKD 202 (6) 214 (5) 38 (7) 106 (9)
G2-Mild 894 (27) 999 (25) 164 (30) 357 (29)
G3a-Mild-Mod 726 (22) 838 (21) 118 (21) 237 (19)
G3b-Mod-Severe 775 (24) 911 (23) 112 (20) 242 (20)
G4-Severe 297 (9) 504 (13) 83 (15) 153 (12)
G5-Kidney failure 18 (1) 50 (1) 15 (3) 38 (3)
Comorbidities
Arrhythmia 1069 (32) 1180 (30) 233 (42) 452 (37)
Diabetes 1596 (48) 1824 (46) 259 (47) 507 (41)
Heart failure 1067 (32) 1146 (29) 285 (51) 563 (46)
Hypertension 2869 (87) 3470 (87) 472 (85) 1078 (87)
IHD 1770 (54) 1981 (50) 213 (38) 445 (36)
Medications
Beta blocker 1453 (44) 1643 (41) 389 (70) 825 (67)
CCB 1152 (35) 1458 (36) 205 (37) 452 (37)
Loop diuretic 1942 (59) 2273 (57) 168 (30) 331 (27)
Spironolactone 416 (13) 432 (11) 144 (26) 279 (23)
Ethnicity
White 3058 (93) 3812 (95)
Black 59 (2) 45 (1)
Asian 119 (4) 85 (2)
Other 35 (1) 26 (1)
Missing 29 (1) 35 (1)
Smoking
Non-smoker 986 (30) 1211 (30)
Ex-smoker 1923 (58) 2360 (59)
Current smoker 378 (12) 425 (11)
Missing 13 (< 1) 7 (< 1)
Alcohol use
Non-drinker 389 (12) 433 (11)
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Admissions
Rates of admissions for all outcomes were highest during
the 30 days after discharge from the baseline AKI event
(participants who were censored due to death or admis-
sion to hospital during this period are described in Add-
itional file 1: Table S3). Compared with those who were
included in the outcome analyses, people excluded in
the 30 days after discharge were older and more likely to
be women, with a higher prevalence of comorbidities
including heart failure and lower baseline eGFR
(Additional file 1: Table S3).
Association of stopping ACEI/ARB with outcomes
In the English cohort, from 30 days after discharge, dur-
ing a median follow-up of 1.1 years (interquartile range
(IQR) 0.4–2.0), 611/7303 (8%) participants experienced a
heart failure outcome, 716/7183 (10%) had AKI, 164/
7438 (2%) a stroke, and 1885/7466 (25%) died. In the
Swedish cohort, again from 30 days after discharge, dur-
ing a median follow-up of 1.4 years (IQR 0.4–2.0), 345/
1790 (19%) participants experienced a heart failure out-
come, 102/1844 (6%) had AKI, 64/1894 (3%) a stroke,
and 516/1903 (27%) died (Additional file 1: Table S4).
The fully adjusted hazard ratios (HR) for heart failure
(primary outcome), AKI, stroke, and death in the English
and Swedish cohorts are shown in Fig. 2 and Additional
file 1: Table S4. The full model for heart failure in both
cohorts, showing different levels of covariate adjustment,
is presented in Additional file 1: Table S5. There was no
difference in risk of admission with heart failure or AKI
in either cohort between those who stopped or contin-
ued ACEI/ARB after discharge. Additionally, in the
English cohort, there was no difference in the risk of
stroke (HR 0.99, 95% CI 0.71–1.38) while in Sweden a
lower risk of stroke was seen in those who stopped
ACEI/ARB (HR 0.56, 95% CI 0.34–0.93). In the English
cohort, but not in the Swedish cohort, we observed an
increased risk of death in those who stopped ACEI/ARB
compared with those who continued (England: HR 1.27,
95% CI 1.15–1.41; Sweden: 0.94, 95% CI 0.78–1.13).
Sensitivity analyses
Propensity score (PS) distribution between exposure
groups before and after PS matching in the English
and Swedish cohorts (bottom figures) are shown in
Additional file 1: Figure S4. Baseline characteristics of
exposure groups for the heart failure outcome analysis
after propensity score (PS) matching and standardised
mean differences (SMD) before and after PS matching
in the English and Swedish cohorts are shown in
Additional file 1: Table S6.
We did not see any important differences from the
main results in the propensity-score-matched analyses
or sensitivity analyses by differing definitions of stop-
ping, by different outcome definitions, or by time
period post discharge for the outcomes heart failure,
AKI, or stroke (Additional file 1: Figure S5 and
Tables S7–10). Results were suggestive that the asso-
ciation between stopping ACEI/ARB and death in the
English cohort became less marked at later time pe-
riods after start of follow-up (HR 1.59 (95% CI 1.21–
2.08) at 0–29 days, 1.41 (95% CI 1.12–1.76) at 30–89
days, and 1.18 (95% CI 1.05–1.33) at more than 90
days (Additional file 1: Table S10)).
Table 1 Baseline characteristics of the English and Swedish cohorts included in the heart failure (primary outcome) analysis
(Continued)
English cohort Swedish cohort
Continued ACEI/ARB Stopped ACEI/ARB Continued ACEI/ARB Stopped ACEI/ARB
N = 3300 N = 4003 N = 555 N = 1235
Current drinker 2133 (65) 2683 (67)
Ex-drinker 611 (19) 713 (18)
Missing 167 (5) 174 (4)
BMI (kg/m2), mean (SD) 29 (7) 29 (7)
BMI (kg/m2)
BMI < 18.5 84 (3) 83 (2)
BMI 18.5–24.9 770 (23) 1019 (25)
BMI 25–29.9 1061 (32) 1278 (32)
BMI ≥ 30 1265 (38) 1484 (37)
Missing 120 (4) 139 (4)
Dialysis during baseline AKI admission 71 (2) 190 (5)
Data are n (%) unless otherwise specified. BMI, alcohol use, smoking, and ethnicity were not available in the Swedish dataset
SD standard deviation, CKD chronic kidney disease, eGFR estimated glomerular filtration rate, eGFR category using KDIGO cut-points without the chronicity
requirement, mod moderate, IHD ischaemic heart disease, CCB calcium channel blockers, BMI body mass index, AKI acute kidney injury
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Discussion
In both England and Sweden, we found no evidence of
an increased rate of admissions for heart failure, AKI, or
stroke among people who stopped ACEI/ARB treatment
following discharge after AKI hospitalisation compared
with people who continued, consistent across all main
and sensitivity analyses. In Sweden, there was a lower
risk of stroke among people who stopped ACEI/ARB al-
though the numbers of stroke events were low and
should be interpreted with caution. In England, but not
in Sweden, there was an increased risk of death among
people who stopped ACEI/ARB.
Our aim was to address an important clinical question
regarding the possible harms and benefits of continuing
or restarting ACEI/ARB after an episode of AKI. We
showed consistent results for heart failure and AKI out-
comes in two well-defined cohorts that contain granular
detail about drug prescribing across two countries with
different health care systems. This strengthens our find-
ings and increases the generalisability of these results.
People who continued ACEI/ARB and those who
stopped were largely similar in terms of observed base-
line characteristics, and a propensity-score analysis in-
cluding detailed adjustment for frailty, a potential
residual confounder, supports our findings.
However, there are also limitations to our study, which
we sought to address through our study design and
sensitivity analyses. The most important is that there are
possible unmeasured differences between the groups
leading to residual confounding. These include the ori-
ginal indication for drug prescription and, in particular,
the presence and severity of left ventricular dysfunction.
We identified AKI using ICD-10 codes which, in Eng-
land, are known to have a high positive predictive value
for AKI, but also a high false-negative rate [12]. This
means that the people included in the cohort are likely
to be true cases for their baseline admission, although
we may have missed less severe AKI admissions. The
high false-negative rate could also have led to differential
misclassification of the AKI outcome if those who con-
tinued ACEI/ARB were more likely to have an admission
coded as AKI, or AKI coded in a higher diagnostic pos-
ition, compared to those who stopped. This would have
biased our effect estimate away from the null. Nonethe-
less, our results suggest no change in risk between ex-
posure groups for subsequent AKI, and results were
robust to changing the definition of the AKI outcome by
coding position.
Lack of information about measures of creatinine in
hospital meant that we could not grade severity of AKI
according to the KDIGO criteria [20]; however, a sensi-
tivity analysis excluding people who required dialysis
during their baseline admission did not alter our results.
We were also unable to ascertain whether the cause of
Fig. 2 Forest plot of fully adjusted hazard ratios comparing people who stopped ACEI/ARB after an admission with AKI to those who continued,
in English and Swedish cohorts, for each of the outcomes studied. Superscript number 1 indicates English models adjusted for age, sex, ethnicity,
smoking, alcohol, BMI, eGFR category, diabetes, arrhythmia, heart failure, hypertension, ischaemic heart disease, beta-blocker, calcium channel
blocker, diuretics, and discharge year. Swedish models adjusted for age, sex, eGFR category, diabetes, arrhythmia, heart failure, hypertension,
ischaemic heart disease, beta-blocker, calcium channel blocker, diuretics, spironolactone, and discharge year
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AKI or misclassification of participants who actually had
progressive chronic kidney disease influenced our re-
sults. We chose a priori not to adjust for creatinine or
potassium levels after discharge in our analysis, as we
thought this would be differentially missing for the sick-
est people who were readmitted before they could have
outpatient blood tests, and blood test results may be on
the causal pathway of the decision to restart ACEI/ARB.
However, where available to clinicians, levels of kidney
function and potassium are likely to influence practice
in routine care.
In defining ACEI/ARB exposure, we did not have data
for in-hospital treatment or discharge prescribing. We
chose our 30-day post-discharge period to define expos-
ure using primary care prescriptions partly because par-
ticipants in England would have been likely to receive
medication ‘to take away’ from hospital. Therefore,
people classified as ‘continuers’ in our analysis could ex-
perience a range of treatment patterns, such as continu-
ing ACEI/ARB without a break and stopping the drugs
for a period but receiving a prescription within 30 days
post AKI discharge. It is also possible that people did
not take the medication as prescribed or that they were
given specific instructions about whether, or when, to
restart ACEI/ARB drugs. These issues could all have led
to exposure misclassification which may have influenced
the risk of subsequent outcomes in ways not captured
by our analysis. Exposure to ACEI/ARB exposure would
be misclassified if people were prescribed the medica-
tions after 30 days. However, the vast majority of pre-
scriptions occurred within 60 days post-discharge, and
our sensitivity analysis re-defining exposure by prescrip-
tion at 60-days showed very similar results to the main
analysis. Because misclassification of treatment with
ACEI/ARB (or not) will become more likely over time,
we censored all observations at 2 years after baseline
AKI; median follow-ups were 1.1 years in England and
1.4 years in Sweden for the heart-failure-outcome
analysis.
Our results show a very high rate of death in this vul-
nerable patient group: In England, 25% of people who
survived to 30 days after discharge from an AKI admis-
sion subsequently died during a median follow-up of 1.1
years, similar to the 27% in 1.4 years’ follow-up in
Sweden. It is plausible that the increased risk of death
seen in those who stopped ACEI/ARB in the English co-
hort may reflect withdrawal of medication in the sickest
people who were being managed with supportive care,
which we were unable to fully account for in our multi-
variable models. This is supported by the hazard ratio
for death decreasing towards the null when stratified by
follow-up time, although this result may also represent
survivor bias owing to ‘depletion of susceptibles’ [21].
Furthermore, the association of stopping ACEI/ARB and
cumulative incidence of heart failure, AKI, and stroke
will be affected by the high competing risk of death from
other causes. However, we chose to undertake our ana-
lysis based on the cause-specific hazard which is appro-
priate for investigating the causal relationship between
therapy use and outcomes [22, 23]. We chose not to
examine death from specific causes as we anticipated
that if frailty was the underlying mechanism we would
see an association between stopping ACEI/ARB and
both cardiovascular and non-cardiovascular causes of
death.
A previous population-based cohort study also looked at
re-admissions and death among a mixed population of
ACEI/ARB users and non-users who experienced AKI
[24]. This study described a protective association between
ACEI/ARB use post-AKI discharge and death (HR 0.85,
95% CI 0.81–0.89), but contrary to our findings found a
higher risk of hospitalisation for a composite outcome that
included kidney events and heart failure (HR 1.28, 95% CI
1.12–1.46). However, this study included people as ex-
posed if they received an ACEI/ARB prescription in the
first 6 months making these results vulnerable to exposure
misclassification and time-dependent confounding. Our
results, which show extremely high rates of death and
other outcomes up to 2 years after the baseline AKI ad-
mission, demonstrate the importance of outcomes in this
period after AKI. Another recent study examined out-
comes for people who experienced an episode of AKI (de-
fined by creatinine changes, in contrast with our work)
and were non-ACEI/ARB users before the episode, with-
out diagnosed heart failure [25]. Consistent with our re-
sults, this study showed no increase in subsequent risk of
AKI among people who were exposed to ACEI/ARB after
discharge (adjusted odds ratio 0.71, 95% CI 0.45–1.12).
Our work adds to these studies by looking specifically at a
range of outcomes among people who were ACEI/ARB
users before they experienced AKI and is therefore closely
aligned with the common clinical dilemma we sought to
study.
Our results support evidence that people who use
ACEI/ARB and are hospitalised for AKI are at high risk
of hospital admission with heart failure, stroke, or recur-
rent AKI, but suggest that this is not predominantly be-
cause of withdrawal of ACEI/ARB [2]. Our study only
included ACEI/ARB users who experience AKI and does
not relate to the rate of AKI among ACEI/ARB users,
which we have previously shown to be 6.4/1000 person-
years (95% CI 6.30–6.50) in England, with only a 12%
higher rate among ACEI/ARB users compared to people
taking other antihypertensives [26].
Conclusion
We found no association between stopping ACEI/ARB
after hospitalisation for AKI with important medium-
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term kidney and cardiovascular outcomes. Further re-
search in cohorts which include data on in-hospital and
discharge prescribing, linked to inpatient and outpatient
kidney function data, would further increase our under-
standing. Clinicians can be reassured that restarting
ACEI/ARB medications in people with evidence-based
indications for long-term treatment after discharge with
AKI is not associated with harm.
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